關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

Global Business NewsGlobal Business News

目前Global Business News文章數, 共 21625 篇 ,以下為 1 - 24 篇 訂閱此列表,掌握最新動態
Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference

A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekly subcutaneous GLP-1 analogs for weight loss. In a Phase 3 study in participants with type 2 diabetes (T2DM) (742-P, 793-P), weekly subcutaneous ecnoglutide resulted in robust HbA1c declines of up to -2.43% from baseline after 24 weeks of treatment, with up to 35.2% of participants reaching normoglycemia (HbA1c <5.7%) and 43.7% with weight reductions ≥5%. Novel amylin analogs (788-P, 789-P) were identified that showed potent in vitro activity. In preclinical models, combination of amylin analogs with ecnoglutide demonstrated a synergistic effect on body weight reduction, with improved efficacy compared to combination of cagrilintide and semaglutide. Moreover, a novel amylin development candidate was identified that is stable at neutral pH, providing the opportunity to co-formulate with ecnoglutide or other GLP-1 analogs to improve ease of use for patients and reduce costs. HANGZHOU, China and SAN FRANCISCO, June 22, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide (XW003) in T2DM patients and from a Phase 1 study for oral ecnoglutide (XW004) in healthy and healthy obese participants, as well as preclinical data for novel amylin analog programs, at the American Diabetes Association (ADA) 84th Annual Conference. Five posters, including one late-breaking poster, will be presented. The ADA conference is being held in Orlando, FL June 21-24, 2024.  Late Breaking Poster Presentation (1871-LB): Saturday June 22, 12:30 PM - 1:30 PM"Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide" Poster Presentation (742-P): Sunday June 23, 12:30 PM - 1:30 PM"A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes" Poster Presentation (793-P): Sunday June 23, 12:30 PM - 1:30 PM"Biased GLP-1 analog ecnoglutide (XW003) has improved efficacy relative to unbiased peptides" Poster Presentation (789-P): Sunday June 23, 12:30 PM - 1:30 PM"Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control" Poster Presentation (788-P): Sunday June 23, 12:30 PM - 1:30 PM"Synergistic Body Weight Reduction of GLP-1 Analog Ecnoglutide and Amylin Analogs in Preclinical Animal Models" About ecnoglutide Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for MASH.  Ecnoglutide is a novel, biased, long-acting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly subcutaneous dosing. Ecnoglutide has demonstrated treatment benefits for patients with type 2 diabetes and obesity and is safe and well tolerated in Phase 1 through Phase 3 clinical studies. About Sciwind Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates, including the long-acting GLP-1 peptide analog XW003 (Phase 3), oral GLP-1 peptide analog XW004 (Phase 1), an oral small molecule GLP-1 receptor agonist XW014 (Phase 1), and novel amylin analogs (preclinical). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com. 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 135 加入收藏 :
New MiniMed™ 780G system data demonstrates ability to address persistent blood sugar challenges for people with type 1 diabetes

With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn phenomenon, and improved overnight sleep DUBLIN and ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes Association's (ADA) 84th Scientific Sessions that showcases the benefits of the MiniMed™ 780G system. New data shows how the system addresses hyperglycemia and nighttime burden, adding to the established body of evidence that demonstrates the system's ability to tackle unique and burdensome challenges of diabetes, such as managing highs and meal-time management or carb counting, while also mirroring outcomes across a wide-ranging patient population.  Tackling hyperglycemia to improve long-term health with type 1 diabetesAmong the burdens of living with diabetes, hyperglycemia can often be overshadowed by hypoglycemia. Yet, in the U.S., only 26% of people living with diabetes achieve HbA1c levels of <7.0%.1 Reducing the time spent with high blood sugars continues to be a significant unmet need as it can lead to serious health problems impacting multiple organs.2 For children, prolonged highs can have adverse effects on memory, IQ, executive functioning, and learning.3 One cause of high blood sugars is the dawn phenomenon, an increase in glucose levels in the early morning.4 This can be a common occurrence for those living with diabetes and may add to feelings of frustration with diabetes. An encouraging new retrospective analysis of real-world data (n= 6026) showed that this morning peak was nearly eliminated for users who upgraded from the MiniMed™ 770G system to the MiniMed™ 780G system. The data assessed the elevation of sensor glucose levels >20 mg/dL from 3 - 6 a.m. compared to 12 – 3 a.m. at least 30% of the nights. The transition from the MiniMed™ 770G system to the MiniMed™ 780G system decreased dawn phenomenon rates from 12.2% to 4.5%. Time in Range also increased from 87.7% to 91.4% from 12 – 6 a.m., which is consistent with dawn phenomenon trends. Early and consistent management of hyperglycemia is critical as it has protective effects on the body that can last for decades.5 "For those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one's control," explained Robert Vigersky, MD, Chief Medical Officer, Medtronic Diabetes. "The introduction of the MiniMed™ 780G system has made it easier to maintain target glucose range with less effort to protect against hyperglycemia.6,7 It's been an absolute gift for my patients who have struggled with stubborn highs throughout their diabetes journey." Reducing nighttime burden  For individuals living with type 1 diabetes, CGM-generated alerts and the need to deliver manual boluses disrupt sleeping through the night adding to the burden of diabetes. The MiniMed™ 780G system is designed to reduce the burden of diabetes throughout the day and night. Additional real-world data from a retrospective analysis presented at ADA (n=8019; <7 y/o, previously on the MiniMed™ 770G system who had greater than 14 nights on both systems) demonstrated that users had fewer overnight sleep interruptions and Time in Range improvements as a result of the automatic adjustments in insulin and correction† of glucose levels every 5 minutes, including during sleep.§ With the MiniMed™ 780G system, nighttime alerts decreased 45% for all users and 55% for those who used recommended optimal settings. Additionally, uninterrupted sleep, a greatly desired outcome for those living with diabetes, increased by 30 and 36 minutes per night, respectively. These results add to the diabetes burden reduction that MiniMed™ 780G system users experience with an advanced algorithm with frequent, every 5-minute autocorrections. The continued evolution of the MiniMed™ 780G system to reduce burdenAlong with evidence on the currently available MiniMed™ 780G system, additional data will be presented on the next iteration of the system,* which aims to further reduce diabetes management burden through its design. The system is intended to be paired with the Simplera Sync™ sensor, a disposable, all-in-one continuous glucose monitor (CGM) designed to require no overtape. A 24-site, single arm study evaluated the use of the next iteration of the MiniMed™ 780G system algorithm paired with the Simplera Sync™ sensor. Results were promising across all clinical outcomes metrics including Time in Range (TIR), Time in Tight Range (TITR) and Time Above Range (TAR), compared to the run-in group where hybrid closed loop (auto basal only) or open-loop delivery was used. The study included the use of recommended optimal settings (ROS) (100 mg/dL set target with an active insulin time of 2 hours) related to TIR, TITR, and TAR. "The MiniMed™ 780G system has firmly established itself as a proven automated insulin delivery system," said study investigator Gregory Forlenza, MD, professor and pediatric endocrinologist at the Barbara Davis Center. "With the next iteration of the system and this next-generation Simplera Sync™ sensor, the overall experience for people living with type 1 diabetes could be enhanced and may prove to be a compelling option for diabetes management — particularly when leveraged in combination with recommended optimal settings." The MiniMed™ 780G system** is currently available for ages 7 and above in over 100 countries globally and will be launching with the Simplera Sync™ sensor in parts of Europe in late July. Currently, Simplera Sync™ is investigational and not approved for commercial use in the U.S.* Safety and Glycemic Outcomes Using the MiniMed™ 780G system with an All-in-OneDisposable Sensor with Transmitter3-month study period (n=109, ages 7-17; n=107, ages 18-80) Youths (ages 7-17) Adults (ages 18-80) Run-in(N=112) Study(N=109) ROS(N=41) Run-in(N=110) Study(N=107) ROS(N=44) Time in Smart Guard,% 14.5±31.3 93.5±11.3 96.9±3.1 33.2±40.3 96.6±6.6 97.5±3.7 Mean SG, mg/dL 180.4±27.1 154.4±17.6 149.0±15.3 161.0±18.7 142.2±12.8 136.5±12.0 Percentage of time spent at glucose ranges <70 mg/dL (% TBR) 1.6±1.7 1.9±1.4 1.9±1.2 1.7±1.9 1.5±1.4 1.7±1.4 70-140 mg/dL (% TITR) 32.1±14.1 49.2±9.7 52.7±9.2 39.2±13.0 56.1±10.5 61.6±9.9 70-180 mg/dL (% TIR) 54.4±15.7 71.4±9.9 74.7±9.3 66.5±12.6 80.2±8.1 83.8±7.4 >180 mg/dL (% TAR) 44.0±16.1 26.7±10.1 23.3±9.4 31.8±13.1 18.2±8.4 14.5±7.7   Caption: Glycemic metrics and insulin delivered during youth and adult MiniMed™ 780G system investigational use with the disposable all-in-one Simplera Sync™ sensor To view this data at the 84th American Diabetes Association (ADA) Scientific Sessions in Orlando, Florida, view the company's previous announcement here for presentation times. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn. About Medtronic Diabetes (www.medtronicdiabetes.com) Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. *Investigational. Not approved by the FDA for any use and not commercially available in the US. **MiniMed™ 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. For details, see https://bit.ly/780gRisks † Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off. § Refers to SmartGuard™ feature. Individual results may vary. Ebekozien O, Mungmode A, Sanchez J, Rompicherla S, Demeterco-Berggren C, Weinstock RS, Jacobsen LM, Davis G, McKee A, Akturk HK, Maahs DM, Kamboj MK. Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016-2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther. 2023 Nov;25(11):765-773. doi: 10.1089/dia.2023.0320. Epub 2023 Oct 16. PMID: 37768677. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993; 329:977-986 Mauras N, Buckingham B, White NH, Tsalikian E, Weinzimer SA, Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL; Diabetes Research in Children Network (DirecNet). Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care. 2021 Apr;44(4):983-992.  O'Neal, Teri B. "Dawn Phenomenon." U.S. National Library of Medicine, 16 May 2023, www.ncbi.nlm.nih.gov/books/NBK430893/.  Lachin JM, Bebu I, Nathan DM; DCCT/EDIC Research Group. The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care. 2021 Aug 11;44(10):2225–30. Arrieta A, Battelino T, Scaramuzza AE, Da Silva J, Castañeda J, Cordero TL, Shin J, Cohen O. Comparison of MiniMed™ 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. Diabetes Obes Metab. 2022 Jul;24(7):1370-1379. Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, Close KL. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019 Mar;42(3):400-405. doi: 10.2337/dc18-1444. Epub 2018 Oct 23. PMID: 30352896; PMCID: PMC6905478. Contacts: Ashley Patterson Ryan Weispfenning Public Relations Investor Relations +1 (818) 576-3025 +1 (763) 505-4626    

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 150 加入收藏 :
FP Markets Adds Two More Industry Benchmark Awards to Its Collection

SYDNEY, June 21, 2024 /PRNewswire/ -- Extending its winning streak, global multi-asset Forex and CFD broker, FP Markets, was crowned 'Most Transparent Broker' and also took home 'Best Trading Conditions' for the second year in a row at the highly anticipated Global Ultimate Fintech (UF) Awards 2024. Following last year's 'Most Trusted Broker' acknowledgement and the 'Best Trade Execution' award received in 2022, the FP Markets trophy cabinet now includes five esteemed Global UF Awards.  FP Markets Adds Two More Industry Benchmark Awards to Its Collection   Established to honour the most outstanding B2C and B2B brands in the online trading and fintech domain and provide traders and businesses with an industry benchmark, the UF Awards are widely considered as one of the sector's most sought-after prizes. Claiming two accolades this year marks another significant milestone in FP Markets' 19-year history, especially since the UF Awards are directly determined by the votes of industry professionals, fintech enthusiasts, and online traders. Invited on stage to receive the award, FP Markets CEO Craig Allison expressed his gratitude and commented: 'The two UF Awards we've won tonight are the embodiment of what we strive to achieve as a company on a daily basis: deliver a superior trading destination for traders while at the same time uphold our core values of integrity, transparency and innovation and we continue to find ways to provide the best possible trading conditions'. The awards ceremony took place at the exclusive Columbia Beach venue in Limassol, Cyprus, as part of the closing party of the 13th iFX EXPO International. With a record-breaking attendance of over 4,000 visitors from 120 countries and 1,400 companies, the iFX EXPO International - one of the flagship gatherings for the trading industry - brought together executives from the world's top financial brands, fintech innovators and other stakeholders.  Earlier in the week,  FP Markets Global Head of Marketing, Andria Phiniefs was a guest on the panel at the iFX Expo's Idea's Hub 'Marketing Beyond the Transaction: Building a Trusted Trading Brand' speaking about the significance of 'brand trust and reputation' as the most important drivers behind the broker's growth strategy. Notes to Editors About FP Markets: FP Markets is a Multi-Regulated Forex and CFDs Broker with over 19 years of industry experience. The company offers highly competitive interbank Forex spreads starting from 0.0 pips. Traders can choose from the leading powerful online trading platforms, including FP Markets' Mobile App, MetaTrader 4, MetaTrader 5, WebTrader, cTrader, Iress and TradingView. The company's outstanding 24/7 multilingual customer service has been recognised by Investment Trends and awarded 'The Highest Overall Client Satisfaction Award' over five consecutive years. FP Markets was awarded 'Best Global Forex Value Broker' for five consecutive years (2019, 2020, 2021, 2022, 2023) at the Global Forex Awards. FP Markets was awarded the 'Best Forex Broker – Europe' and the 'Best Forex Partners Programme – Asia' at the Global Forex Awards 2022 and 2023. FP Markets was awarded 'Best Trade Execution', and 'Most Trusted Broker' and 'Best Trade Execution' at the Ultimate Fintech Awards 2022 and 2023. FP Markets was crowned 'Best CFD Broker in Africa' at FAME Awards 2023. FP Markets was awarded 'Best Trade Execution' and 'Most Transparent Broker' at the Ultimate Fintech Awards APAC 2023. FP Markets regulatory presence includes the Australian Securities and Investments Commission (ASIC) Financial Sector Conduct Authority (FSCA) of South Africa, the Financial Services Commission (FSC) of Mauritius, the Cyprus Securities and Exchange Commission (CySEC), the Securities Commission of the Bahamas (SCB) and the Capital Markets Authority (CMA) of Kenya. FP Markets was awarded the Best Price Execution Award at the Brokersview Awards 2024 Singapore. FP Markets was awarded the 'Best Trading Experience - Africa' at FAME Awards 2024. For more information on FP Markets' comprehensive range of products and services, visit https://www.fpmarkets.com/  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 145 加入收藏 :
2024 World Intelligence Expo Begins with a Grand Opening in Tianjin

TIANJIN, China, June 22, 2024 /PRNewswire/ -- On June 20th, Tianjin hosted the opening of the 2024 World Intelligence Expo (WIE). Under the theme "Intelligence: Expansive Development Space, Sustainable Growth Driver," the event was co-organized by the people's governments of the Tianjin and Chongqing municipalities. Wan Gang made a keynote speech. Chinese President Xi Jinping sent a congratulatory letter to the expo, pointing out that AI, as an important driving force for a new round sci-tech revolution and industrial transformation, will have a far-reaching impact on global economic and social development and human civilization progress. In his letter, Xi also noted that China has attached great importance to the development of AI, actively driven the deep integration of the Internet, big data and AI with real economy to cultivate and build the intelligent industry, accelerate the development of new quality productivity, and provide new momentum for high-quality development. Chen Min'er, secretary of the CPC Tianjin Committee, addressed the opening ceremony of the expo. Wan Gang, chairman of China Association for Science and Technology, delivered the keynote speech. Hu Henghua, mayor of Chongqing; Wu Zhaohui, vice president of Chinese Academy of Sciences; Liu Liehong, head of the National Data Administration; Long Teng, vice minister of the Ministry of Science and Technology; and Shan Zhongde, vice minister of the Ministry of Industry and Information Technology, addressed the expo, respectively. Tianjin Mayor Zhang Gong presided over the opening ceremony. In his speech, Chen Min'er pointed out that Tianjin has been adhering to sci-tech innovation and industrial innovation at the same time, actively propelling exploration and practical applications in the realm of AI, and accelerating the development of new quality productivity to better empower its high-quality development and living. Chen added, "Leading sci-tech innovation with intelligence, Tianjin will rev up the R&D and application of some key core technologies, vigorously develop the sci-tech service sector, streamline the supply and demand channels for sci-tech achievements, boost sci-tech and innovation parks to improve their quality and efficiency, and accelerate the inter-sector application of AI to help innovation and breakthroughs in the fields of life science, low-carbon technology, and future research. According to Hu Henghua, Chongqing is speeding up in digital industrialization and industrial digitization to build itself into a new digital economy highland. The 2025 World Intelligence Expo is scheduled to be held in Chongqing. Hu invited everyone to delineate a new AI landscape together, share golden opportunities during the digitization of Chongqing, and co-build a promising future in the AI era. Wu Zhaohui suggested strengthening the inter-discipline cooperation to consolidate the AI research foundation, enriching AI scenarios with applets, and deepening industry-institute interactions to build an AI innovation ecosystem. Zeng Yi, chairman of China Electronics Corporation; Chen Zhongyue, chairman of China Unicom; Yang Yuanqing, chairman and CEO of Lenovo; and Zhou Hongyi, founder of Qihoo 360 delivered speeches. Contact: Xing MeiqiTel: 0086-22-28209030E-mail: maggiesing@vip.126.com The site of 2024 World Intelligence Expo

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 104 加入收藏 :
Discover VIAIM's Advanced Earbuds: Elevate Your Smart Office Experience with Real-time Conference Recording"

HEFEI, China, June 21, 2024 /PRNewswire/ -- VIAIM, an AI technology hardware company deeply rooted in the smart office sector, has announced the upgrade of its brand-new official website, showcasing its innovative wireless earbuds. The upgraded website put spotlight on its flagship products, the AI Recoding True Wireless Earbuds VIAIM Nano+ and the Open-ear AI Recording True Wireless Earbuds VIAIM Air earbuds, unleashing a more efficient and intelligent smart office experience for customers around the globe. By prioritizing user needs, VIAIM ensures that its offerings not only meet but exceed customer expectations. creating a seamless and user-centric interaction with innovative smart office solutions. The VIAIM Series products boast some of the most impressive features including the Recording Transcription Function, which provides real-time recording for various scenarios such as field, call, audio, and video, and can summarize full meetings into a digestible abstract with one click; the Multi-Language Translation that supports 11 languages for cross-language meetings and learning. It also comes with VIAIM AI technology that transforms meetings into written records with real-time audio-to-text transcription, generating concise summaries and post-meeting action items.  Dedicated to producing high-quality products that offer emotional and personalized multimodal hybrid interactions that genuinely address user issues, VIAIM strives to transform our visions of the future into reality through technological means, enabling everyone to enjoy the wonders of future intelligence. The robust technical expertise of the VIAIM team allows for quick and effective empowerment in the intelligent hardware arena, leading to the development of the powerful VIAIM Nano series of conference headphones. These headphones represent a "new breed" in the market, enhancing the efficiency of conference office activities. Ma Xiao, CEO of VIAIM, said: "We aim to showcase how future smart products can enhance efficiency and convenience. In AIGC, service tools for vertical scenarios are more practical than general intelligence tools. VIAIM office data has formed a Matthew effect, creating a practical AI conference assistant for the vertical scenario of office meetings. Through continuous upgrades of VIAIM AI, we have successfully evolved conference headphones from "intelligent tools" to "intelligent assistants", becoming one of the most practical AIGC smart office headphones for office meetings. We have been trendsetters in AIGC applications with constantly realized dreams and product technology strength." "VIAIM delivers high-quality, emotionally engaging, and personalized products to users in 154 countries.In 2023, sales on JD.com and Tmall during major shopping festivals increased 13-fold year-on-year, While TikTok platform sales rose 30-fold. Online sales grew 4-fold in Q4 2023 and continued stable growth in Q1 2024. Offline, VIAIM's products are available in over 1,000 outlets. Established in 2021, VIAIM's team has over a decade of AI expertise. From 2011 to 2014, they researched AI assistants, achieving advancements in speech recognition and semantic analysis. VIAIM's upgraded official website highlights its innovative products aimed at enhancing office efficiency and the smart office experience for global users. Their cutting-edge technology and forward-thinking approach to future smart applications set the trend in AIGC solutions. About VIAIM VIAIM is an AI technology hardware company deeply rooted in the smart office sector. We have always been committed to creating high-quality products with emotional engagement and personalization, multi-modal mixed interaction, and can truly solve user problems, bringing our expectations for the future to reality through scientific and technological means, so that everyone can experience the beauty of future intelligence.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 145 加入收藏 :
Neusoft Invited to Deliver Keynote Speech at AEK 2024

LUDWIGSBURG, Germany, June 22, 2024 /PRNewswire/ -- At the 28th International Automobil-Elektronik Kongress (AEK) 2024, Dr. Angela Wang, Senior Vice President & Chief Investment Officer of Neusoft Corporation (Neusoft, SSE: 600718) and Chairman & President of Neusoft Europe, was invited to deliver a keynote speech on the topic of "Build New Ecosystem with China Market to Win in the Era of Software-Defined Vehicle", contributing a meaningful perspective from China to the discussions at the conference. She shared her insights on China's market trends and innovation dynamics, opportunities of global collaborations, and how Chinese technology partners support global automakers to innovate. As a pinnacle gathering for automotive electronics professionals worldwide, the Automobil-Elektronik Kongress brings together over 600 industry experts, researchers, and innovators to discuss the latest advancements and future trends in automotive electronics. In her speech, Dr. Angela Wang said, "Today, SDV is entering the deep water area, and we are facing unprecedented multi-dimensional challenges. Automakers are trying to build diverse collaboration and dynamic ecosystems with various technology partners. As an emerging player, China is attracting increasing global attention. Driven by Chinese consumers' strong enthusiasm and preferences for electric and intelligent features of cars, China not only became the largest consumer market for intelligent cars, but also serves as a new test base for technological innovation and experience, and such dynamics brought severe competition in the aspects of innovation, speed and cost. Chinese technology partners who survive in the competition have experienced large amount of meaningful trial and error, and have fast speed, flexible business models, deep capability reserves and hardworking teams. Looking into the future, despite the differences between regional markets, global collaboration must be a major trend. By integration of their different DNA and respective advantages, China technology partners can work together with global automakers to help them achieve swift time to market, innovation dynamics, SDV-ready talents, ecosystem resources, flexibility and resilience." Neusoft is an industry-leading information technology, products and solutions company for global market. In the field of automotive, Neusoft is committed to be the software innovation partner for global automakers in the era of SDV. Neusoft has more than 30 years of R&D experience in automotive software, and established a global product R&D and delivery network centered in China, Germany, US, Japan and Malaysia, with 6,000+ automotive software engineers. Neusoft's automotive products have been applied to 220+ car models, across 100+ countries, for 50+ OEMs. In the future, Neusoft will continue to empower global automakers with continuous innovation, collaborate with stakeholders in the ecosystem, to promote the transformation of the auto industry, and bring more fantastic experiences for global consumers. For more information about Neusoft, please visit www.neusoft.com.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 139 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈